Indian pharmaceutical company Indoco Remedies receives final USFDA approval for generic Lofexidine tablets, granting 180-day CGT exclusivity.

Indian pharmaceutical company Indoco Remedies received final USFDA approval for its generic Lofexidine tablets, used in opioid discontinuation treatment, granting them 180 days of competitive generic therapy (CGT) exclusivity. As the first approved generic, Indoco Remedies plans to launch the product immediately in the US market, targeting a $15.59m market with 38% growth potential. The drug's estimated sales enable the company to strengthen its position in the US market.

August 21, 2024
7 Articles